- Two Carragelose nasal sprays have received declaration of conformity under the new medical device regulation - certificates for further products expected later in the year
- Extensive clinical data for Carragelose facilitates challenging demands for MDR transition
- MDR-compliance is a major asset for medical devices and adds significant value to Carragelose portfolio
- Evaluation process regarding strategic options for the Carragelose business ongoing; due diligence phase continuing but no agreements made to date
The full press release is available as download here: